Not Yet RecruitingPhase 2

QLS1410 in Participants With Uncontrolled Hypertension

260 participantsStarted 2026-04

Plain-language summary

The goal of this clinical trial is to measure the efficacy and safety of QLS1410 in participants with uncontrolled hypertension (uHTN) or treatment-resistant hypertension (rHTN). The main objective is to compare the difference in systolic blood pressure（SBP) change from baseline at Week 12 of treatment between participants receiving QLS1410 tablets and participants receiving placebo tablets.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female participants must be ≥ 18 years old.
✓. Mean seated SBP ≥ 140 mmHg at Screening and at Baseline..
✓. Fulfil at least 1 of the following 2 criteria:

Exclusion criteria

✕. Mean seated systolic blood pressure (SBP)≥ 180 mmHg.
✕. Mean seated diastolic blood pressure (DBP)≥ 110 mmHg.
✕. Estimated glomerular filtration rate \< 45 mL/min/1.73m2.
✕. Serum potassium (K+) level \<3.5 and ≥ 5.0 mmol/L.
✕. Has the following known secondary causes of hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation.
✕. NYHA functional heart failure class IV at Screening.

What they're measuring

Change from baseline in mean seated systolic blood pressure (SBP) at week 12

Timeframe: At week 12

Trial details

NCT IDNCT07489612

SponsorQilu Pharmaceutical Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-12

Contact for this trial

Yuguo Chen, PhD

+86-0531-82169023 chen919085@126.com

View on ClinicalTrials.gov More Hypertension (HTN) trials